SynthesisMedicine2018

The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.

Xianying Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.